8-K: HealthLynked Corp. Secures $900,000 in Funding via Convertible Notes and Warrants
Financing Agreement
HealthLynked Corp. has entered into a financing agreement, issuing convertible notes and warrants to the Mary S. Dent Gifting Trust for a total of $900,000.
Summary
- HealthLynked Corp. has secured $900,000 through the issuance of ten senior secured convertible promissory notes and a warrant to the Mary S. Dent Gifting Trust.
- The notes were issued with a 5% original issue discount, resulting in net proceeds of $855,000 for the company.
- The funds were advanced in installments between July 10, 2024, and September 10, 2024.
- Each note matures six months from the date of its respective cash advance.
- The notes accrue interest at 12% per annum, increasing to 18% upon an uncured event of default.
- The notes are convertible into common stock at a price of $0.0486 per share.
- The warrant allows the purchase of 9,259,258 shares of common stock at an exercise price of $0.0486 per share and has a 10-year term.
- The company's obligations are secured by a first-priority lien on all of its assets.
- The proceeds will be used for working capital and general corporate purposes.
Sentiment
Score: 4
Explanation: The sentiment is moderately negative due to the high interest rate, the first-priority lien on all assets, and the potential for significant dilution. While the company has secured funding, the terms suggest a weaker financial position and higher risk for investors.
Positives
- The company has successfully secured a significant amount of funding to support its operations.
- The convertible notes provide flexibility for both the company and the investor.
- The warrant provides potential for future equity participation for the investor.
- The funds will be used for working capital and general corporate purposes, which can support growth.
Negatives
- The notes are secured by a first-priority lien on all of the company's assets, which could be a risk for the company.
- The interest rate on the notes increases to 18% upon an event of default, which could be costly for the company.
- The conversion price of $0.0486 per share could lead to significant dilution if the notes are converted.
Risks
- The company's obligations are secured by a first-priority lien on all of its assets, which could be a risk for the company if it defaults on the notes.
- The increase in the interest rate to 18% upon an event of default could put a strain on the company's finances.
- The conversion of the notes and exercise of the warrants could lead to significant dilution of existing shareholders.
- The company's ability to meet its obligations under the notes and security agreement is dependent on its future financial performance.
Future Outlook
The company intends to use the proceeds from the sale of the convertible notes for working capital and general corporate purposes.
Industry Context
This type of financing, involving convertible notes and warrants, is common for small to medium-sized companies seeking capital, particularly in the healthcare and technology sectors. It allows for immediate funding while providing potential future equity upside for investors.
Comparison to Industry Standards
- The terms of the convertible notes, including the interest rate and conversion price, are within the typical range for similar financings in the micro-cap market.
- The 5% original issue discount is a common feature in such transactions, reflecting the risk associated with investing in smaller companies.
- The 12% interest rate, increasing to 18% upon default, is relatively high, indicating the perceived risk of the investment.
- The conversion price of $0.0486 per share is low, which is typical for companies with a low share price, and could lead to significant dilution if the notes are converted.
- The 10-year term of the warrant is also a common feature, providing long-term potential for the investor.
Related Party Transactions
- The Purchaser, Mary S. Dent Gifting Trust, is controlled by the Chief Executive Officer and Chairman of the Company, Dr. Michael Dent.
Stakeholder Impact
- Shareholders may experience dilution if the notes are converted and warrants are exercised.
- Employees may benefit from the company's improved financial position.
- Creditors may be impacted by the first-priority lien on all of the company's assets.
- Customers and suppliers may see no immediate impact.
Next Steps
- The company will use the proceeds for working capital and general corporate purposes.
- The company will need to manage its debt obligations and interest payments.
- The company may need to seek additional funding in the future.
- The company will need to monitor the conversion of the notes and exercise of the warrants.
Key Dates
| Date | Description |
|---|---|
| July 10, 2024 | First cash advance date for one of the convertible notes. |
| July 16, 2024 | Cash advance date for two of the convertible notes. |
| July 19, 2024 | Cash advance date for one of the convertible notes. |
| July 30, 2024 | Cash advance date for one of the convertible notes. |
| August 14, 2024 | Cash advance date for one of the convertible notes. |
| August 20, 2024 | Cash advance date for one of the convertible notes. |
| August 28, 2024 | Cash advance date for one of the convertible notes. |
| September 4, 2024 | Cash advance date for one of the convertible notes. |
| September 10, 2024 | Last cash advance date for one of the convertible notes. |
| September 19, 2024 | Date of the Notes and Warrant Purchase Agreement, Security Agreement, and issuance of the notes and warrant. |
| September 24, 2024 | Date of the 8-K filing. |
| January 10, 2025 | Maturity date for one of the convertible notes. |
| January 16, 2025 | Maturity date for two of the convertible notes. |
| January 19, 2025 | Maturity date for one of the convertible notes. |
| January 30, 2025 | Maturity date for one of the convertible notes. |
| February 14, 2025 | Maturity date for one of the convertible notes. |
| February 20, 2025 | Maturity date for one of the convertible notes. |
| February 28, 2025 | Maturity date for one of the convertible notes. |
| March 4, 2025 | Maturity date for one of the convertible notes. |
| March 10, 2025 | Maturity date for one of the convertible notes. |
| September 18, 2034 | Termination date of the warrant. |
Keywords
convertible notes, warrants, financing, secured debt, equity securities, HealthLynked Corp, capital raise, promissory notes
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.